Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The activity of GOT, GPT, APh, liver APh, gamma GTP, AAP and serum cholinesterase were determined in 80 patients with chronic liver diseases, diagnosed clinically, laparoscopically and by liver biopsy. Out of the patients with liver cirrhosis (51), those with portal cirrhosis (40) have a considerably higher activity of gamma GTP, intestinal APh than the patients with postecrotic cirrhosis (11). Cholinesterase activity is markedly lower in patients with cirrhosis and ascites than in the patients without ascites. With the histological data about the activity gamma GTP and GOT are considerably higher without activity. Examinations were carried out also upon patients with chronic aggressive hepatitis (4), chronic persisting hepatitis (9), liver cancer (12) and liver steatosis (4). The data revealed that the majority of the enzymes are with a higher sensitivity (especially gamma GTP, GOT, liver APh, cholinesterase) but with more restricted diagnostic and differential-diagnostic potentialities in view of the great dispersion of the enzyme activities with the separate liver diseases.
 ...
PMID:[Comparative laparoscopic, bioptic and clinical enzymological studies in liver cirrhosis and other chronic liver diseases]. 14 93

Abnormal serum aminotransferase activities with dominance of aspartate aminotransferase over alanine aminotransferase activity, and elevated serum adenosine deaminase activity and immunoglobulin. A concentration, were commonly encountered among patients with portal cirrhosis. The full triad was present in 31 of 49 cases (63%). As isolated abnormalities, these features were not uncommon in patients with other diseases of the liver and biliary tree, but the full triad was found only in 11 of 163 such cases (6.8%). The presence of this triad in a patient with unexplained hepatomegaly is indicative of portal cirrhosis.
 ...
PMID:A diagnostic triad for portal cirrhosis. 97 89

The effect of human placenta hydrolysate (Laennec) on residual liver regeneration after about 70% partial hepatectomy (PH) in normal and CCl4-induced cirrhosis rats was examined. Both intravenous or subcutaneous injections of Laennec increased the regeneration rate of the residual liver after PH in normal rats. Intravenous injection of Laennec inhibited the decrease of liver total protein, and it decreased the level of serum transaminase (GOT, GPT). The regeneration rate of the residual liver after PH in CCl4-induced cirrhosis (CCl4-PH) rats increased by intravenous or subcutaneous injection of Laennec. Laennec also inhibited the increase of serum GOT caused by CCl4-PH. In the pathological examination of the regenerating liver, intravenous injection of Laennec minimized the pathological changes caused by PH or CCl4-PH such as vacuolation and necrosis in the hepatocytes. The enhancement of cytoplasma regeneration in hepatocytes was noticed by intravenous injection of Laennec, but that by subcutaneous Laennec was slight. Intravenous injection of Laennec also minimized the lipid deposition in liver caused by CCl4-PH. Laennec had no effect on the pseudolobule formation caused by CCl4. Thus, the effect of intravenous injection of Laennec on the liver regeneration in PH rats was much more potent than that by the subcutaneous injection.
 ...
PMID:[A comparative study of human placenta hydrolysate (Laennec) by intravenous or subcutaneous injection on liver regeneration after partial hepatectomy in normal and CCl4-induced cirrhosis rats]. 261 8

The effect of Laennec (human placenta hydrolysate) on CCl4-induced acute or chronic liver injury in rats was examined. In the acute liver injury induced by CCl4, 0.5 ml/kg for 4 days, intravenous injection of Laennec increased total protein and decreased nonesterified fatty acid in the liver. Subcutaneous injection of Laennec inhibited the decrease of liver phospholipid by CCl4 administration. Both intravenous and subcutaneous injections of Laennec inhibited the increases of serum transaminase (GOT, GPT) levels caused by CCl4. Furthermore, intravenous Laennec inhibited the increase of serum alkaline phosphatase level. Pathological examinations of the liver indicated that both intravenous and subcutaneous injections of Laennec inhibited the loss of cytoplasma and nuclei, vacuolation, swelling and necrosis in the centrizonal hepatocytes caused by CCl4. Intravenous and subcutaneous injection of Laennec also inhibited the increases of GOT and GPT levels in rats with chronic liver injury caused by CCl4, 0.5 ml/kg for 7 weeks. Both intravenous and subcutaneous injections of Laennec minimized the pathological changes of the liver by CCl4 such as vacuolation, necrosis and swelling of nuclei, but did not inhibit the formation of pseudolobules. Thus, no therapeutic difference was noted between intravenous and subcutaneous injections of Laennec.
 ...
PMID:[A comparative study of Laennec by intravenous or subcutaneous injection on CCl4-induced acute or chronic liver injury in rats]. 280 70

The authors have analyzed findings from a laboratory examination of 50 subjects presenting with different affections of the liver. Correlation is established between the level of total cholesterol and activity of alanine aminotransferase in blood serum of cirrhotic patients, it being particularly clear in portal cirrhosis (r = -0.85; P < 0.05), as well as significantly higher levels of total and indirect bilirubin and lower level of albumins in patients presenting with a reduced level of total cholesterol. This allows the decrease in the blood serum content of total cholesterol to be regarded as an unfavourable index in hepatocirrhosis.
 ...
PMID:[Liver function and the level of total cholesterol in the blood serum in liver cirrhosis]. 1020 56

The effect of Laennec, a hydrolyte of human placenta, on immune-mediated liver injury was investigated in vivo and in vitro in murine. Vena caudalis administration of concanavalin A (Con A) was employed to establish an in vivo liver-injury model, and in vitro hepatotoxicity was induced by 8 h interaction between Con A pre-treated hepatocytes and Con A-stimulated autologous splenic lymphocytes. Laennec was used for pre-treatment in the two models. Laennec decreased biochemical marker activity (alanine aminotransferase, ALT; lactate dehydrogenase, LDH) in serum and recovered the activity of superoxide dismutase (SOD) and myeloperoxidase (MPO), as well as the content of malondialdehyde (MDA) and nitric oxide (NO) in liver tissue. We also found that the DNA ladder induced by Con A in vivo was attenuated by Laennec. Furthermore, the leakage of aspartate aminotransferase (AST) and LDH in the supernatant of the co-culture system was decreased by addition of Laennec. Potential protective mechanisms were elucidated by DNA fragmentation assay and intercellular adhesion molecule-1 (ICAM-1) induction/inhibition experiments. Results showed that ICAM-1, which is related to the interaction between hepatocytes and lymphocytes, was inhibited by Laennec. These findings indicated that Laennec has potent activity against immune-mediated liver injury.
 ...
PMID:Laennec protects murine from concanavalin A-induced liver injury through inhibition of inflammatory reactions and hepatocyte apoptosis. 1898 70